<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232581</url>
  </required_header>
  <id_info>
    <org_study_id>1211.1</org_study_id>
    <nct_id>NCT02232581</nct_id>
  </id_info>
  <brief_title>Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure</brief_title>
  <official_title>Randomised, Double Blind, Placebo-controlled Dose Ranging Trial to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective was to determine the mean change in HIV viral load from baseline to&#xD;
      Week 4 compared with placebo after 4 weeks of treatment in highly experienced HIV-infected&#xD;
      patients.&#xD;
&#xD;
      Secondary objectives were to determine (1) the tolerability, hematologic and hepatic safety&#xD;
      of different doses of alovudine and (2) the effect of baseline nucleoside genotypic&#xD;
      susceptibility on virologic response after 4 weeks of alovudine administration&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in HIV viral load measured from plasma samples</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of virologic responders per treatment arm</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing a change of viral load</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
    <description>viral load of ≥1 log10 from baseline to Week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD4+ cell count</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of 0.5 virologic responders per treatment arm</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of load responders per treatment arm</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of 0.7 to 0.9 virologic responders per treatment arm</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with laboratory test abnormalities and with respect to Division of AIDS (DAIDS) grading</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with serious adverse events</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who discontinued due to adverse event</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in CD8+ cell count</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>Up to 4 weeks after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Alovudine - low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alovudine - medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alovudine - high</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alovudine - low</intervention_name>
    <arm_group_label>Alovudine - low</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alovudine - medium</intervention_name>
    <arm_group_label>Alovudine - medium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alovudine - high</intervention_name>
    <arm_group_label>Alovudine - high</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Alovudine - low</arm_group_label>
    <arm_group_label>Alovudine - medium</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent before any trial procedure&#xD;
&#xD;
          -  HIV-1 infected males or females ≥18 years of age&#xD;
&#xD;
          -  Screening genotypic resistance report indicating two or more of the following&#xD;
             nucleoside reverse transcriptase inhibitors (NRTI) resistance mutations: 41, 67, 70,&#xD;
             210 and 215&#xD;
&#xD;
          -  Stable NRTI regimen without stavudine and zidovudine for at least 6 weeks before&#xD;
             screening and stable antiretroviral (ARV) background treatment for 3 months before&#xD;
             screening&#xD;
&#xD;
          -  HIV-1 viral load ≥1000 copies/mL and &lt;75,000 copies/mL at screening&#xD;
&#xD;
          -  Change in viral load between previous test within 3 months before screening, using&#xD;
             local laboratory for routine tests, and screening test was &lt;1.0 log10 copies/mL&#xD;
&#xD;
          -  Acceptable medical history, as assessed by the investigator&#xD;
&#xD;
          -  Current stable ARV medication regimen between screening (Visit 1) and Visit 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ARV medication naïve&#xD;
&#xD;
          -  Patients on recent drug holiday, defined as off ARV medications for at least 7&#xD;
             consecutive days within the previous 3 months&#xD;
&#xD;
          -  Female patients of child-bearing potential who :&#xD;
&#xD;
               -  have a positive serum pregnancy test&#xD;
&#xD;
               -  are breast feeding,&#xD;
&#xD;
               -  are planning to become pregnant, or&#xD;
&#xD;
               -  are not willing to use a barrier method of contraception&#xD;
&#xD;
          -  Prior alovudine use&#xD;
&#xD;
          -  Use of investigational medications within 30 days before study entry or during the&#xD;
             trial&#xD;
&#xD;
          -  Use of immunomodulatory drugs within 3 months before study entry or during the trial&#xD;
             (e.g. interferon, cyclosporine, hydroxyurea, interleukin-2)&#xD;
&#xD;
          -  Current use of rifampin, rifabutine, isoniazid, pyrazinamide, stavudine, zidovudine,&#xD;
             ganciclovir, chronic use of hepatotoxic drugs, anti-tumour therapy or probenecid&#xD;
&#xD;
          -  Laboratory values:&#xD;
&#xD;
               -  Neutrophils of Grade 2 or greater abnormality&#xD;
&#xD;
               -  Hemoglobin of Grade 2 or greater abnormality&#xD;
&#xD;
               -  Platelets: Grade 2 or greater abnormality&#xD;
&#xD;
               -  Creatinine of ≥1.25 Upper limit of the normal (ULN)&#xD;
&#xD;
               -  Lipase of Grade 1 or greater abnormality&#xD;
&#xD;
               -  Alanine aminotransaminase (ALT) or Aspartate aminotransaminase (AST) of Grade 2&#xD;
                  or greater abnormality&#xD;
&#xD;
               -  Direct bilirubin of Grade 1 or greater abnormality&#xD;
&#xD;
          -  CD4 ≤50 cells/mm3&#xD;
&#xD;
          -  Hepatitis B (+HBsAg or +HBcAB) or C +Hepatitis C virus (+HCV AB ) co-infection,&#xD;
             chronic hepatitis, on-going hepatitis or pancreatitis&#xD;
&#xD;
          -  Any new or active AIDS-defining event within 30 days before study entry&#xD;
&#xD;
          -  Inability to adhere to the requirements of the protocol, including active substance&#xD;
             abuse as assessed by the investigator&#xD;
&#xD;
          -  In the opinion of the investigator, likely survival of less than 6 months because of&#xD;
             underlying disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alovudine</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

